a School of Pharmacy, Guangdong Pharmaceutical University , Guangzhou , China.
b School of Basic Science, Guangdong Pharmaceutical University , Guangzhou , China.
Drug Dev Ind Pharm. 2019 May;45(5):695-702. doi: 10.1080/03639045.2018.1529788. Epub 2019 Feb 20.
The purpose of this study was to prepare a novel cryptotanshinone-loaded nanoemulsion (Cry LN) and to evaluate its prevention effect on the postoperative peritoneal adhesions (PPA). The Cry LN was prepared by high-pressure homogenization method, and various methods were used to investigate the physicochemical properties. The results showed that Cry LN has nanoscale particle size with uniform distribution and could slowly release the incorporated drug compared with Cry solution. With superior safety, Cry LN could increase the ratio of tissue plasminogen activator (tPA)/plasminogen activator inhibitor-1 (PAI-1) up to 673% compared with control group. Furthermore, in vivo animal study confirmed the Cry LN activated the fibrinolytic system and successfully prevented PPA formation in rat. In conclusion, Cry nanoemulsion could be considered as a potentially promising and effective strategy for PPA treatment.
本研究旨在制备一种新型隐丹参酮纳米乳(Cry LN),并评价其对术后腹膜粘连(PPA)的预防作用。Cry LN 通过高压均质法制备,并用各种方法考察其理化性质。结果表明,Cry LN 具有纳米级粒径且分布均匀,并能较 Cry 溶液缓慢释放包载药物。Cry LN 具有良好的安全性,与对照组相比,可使组织型纤溶酶原激活物(tPA)/纤溶酶原激活物抑制剂-1(PAI-1)比值增加 673%。此外,体内动物研究证实,Cry LN 能激活纤维蛋白溶解系统,成功预防大鼠 PPA 的形成。总之,Cry 纳米乳可作为一种有前途的、有效的 PPA 治疗策略。